Jingsong Zhang, MD, PhD, discusses contributing factors to risk stratification and subsequent treatment selection in patients with metastatic castration-sensitive prostate cancer. The factors Zhang highlights include site of metastases, PSA response, and metastases burden.
Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.
Study evaluates polygenic risk score for prostate cancer risk prediction
March 18th 2023“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.
Rise in prostate cancer observed after USPSTF recommendation against screening
March 15th 2023"The government is spending more in Medicare, we are getting more people with prostate cancer, more deaths with prostate cancer, [and] more metastasis with prostate cancer. While it is so simple: today, PSA is still there," says Navin Shah, MD, MS, FACS, FICS, FACIP.
2 Clarke Drive
Cranbury, NJ 08512